Caitlin M. Gibson

Dr. Caitlin M. Gibson


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
AFAlexander H. Flannery
Alexander H. Flannery
MSMate M. Soric
Mate M. Soric
SBSandra Benavides
Sandra Benavides
LBLaura J. Bobbitt
Laura J. Bobbitt
ACAlexandre Chan
Alexandre Chan
TSTerry L. Schwinghammer
Terry L. Schwinghammer
Introduction: The American College of Clinical Pharmacy (ACCP) Pharmacotherapy Didactic Curriculum Toolkit was created by the 2008 ACCP Educational Affairs Committee to provide guidance to schools and colleges of pharmacy for didactic pharmacotherapy curricular development. The toolkit was revised and updated by the 2016 ACCP Educational Affairs Committee.Objectives: In accordance with the ACCP Board of Regents decision to update the toolkit every 3 years, the 2019 ACCP Publications Committee was charged with updating the 2016 toolkit to guide adequate disease state inclusion and depth of pharmacotherapy coverage in pharmacy curricula.Methods: The committee retained the competency‐based tier definitions and organization of the 2016 toolkit. Multiple literature resources were reviewed to assess medical conditions responsive to drug therapy for inclusion in the 2019 toolkit. The committee also reviewed the tier designation for all toolkit entries for appropriateness, given recent advances in medical care and evolving patient care responsibilities of clinical pharmacists. Updates to the toolkit were made by consensus with electronic voting when required.Results: The 2019 toolkit contains 302 topics, including 94 (31%) tier 1, 133 (44%) tier 2, and 75 (25%) tier 3 entries. There are 26 additional topics in the updated toolkit, including 12 new tier 1 topics that are generally treated with nonprescription medications. Eleven new topics were added to tier 2, and 20 topics were added to tier 3 (including 11 topics in the Oncologic Disorders section). The tier classification of some conditions was changed to reflect current pharmacy practice expectations.Conclusion: As with the 2016 toolkit, the large number of tier 1 topics will require schools and colleges to employ creative teaching strategies to achieve practice competence in all graduates. The large number of tier 2 topics highlights the importance of postgraduate training and experience for pharmacy graduates desiring to provide direct patient care.

29 February 2024 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
DKDenise M. Kolanczyk
Denise M. Kolanczyk
JMJessica R. Merlo
Jessica R. Merlo
BBBridget Bradley
Bridget Bradley
AFAlexander H. Flannery
Alexander H. Flannery
CGCaitlin M. Gibson
Caitlin M. Gibson
KTKrisy‐Ann Thornby
Krisy‐Ann Thornby

1 July 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
CGCaitlin M. Gibson
Caitlin M. Gibson
LCLindsey Childs-Kean
Lindsey Childs-Kean
ZNZahra Naziruddin
Zahra Naziruddin
CHCrystal K Hodge
Crystal K Hodge

1 October 2014 in Journal of Critical Care
Verified
Journal Article
Closed access
CGCaitlin M. Gibson
Caitlin M. Gibson
SPSteven E. Pass
Steven E. Pass

26 December 2019 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
CGCaitlin M. Gibson
Caitlin M. Gibson
WYWei C. Yuet
Wei C. Yuet
Introduction: Anticoagulants are among the most frequently prescribed medications in the United States. Racial and ethnic disparities in incidence and outcomes of thrombotic disorders are well-documented, but differences in response to anticoagulation are incompletely understood. Objective: The objective of this review is to describe the impact of race and ethnicity on surrogate and clinical end points related to anticoagulation and discuss racial or ethnic considerations for prescribing anticoagulants. Methods: A PubMed and MEDLINE search of clinical trials published between 1950 and May 2018 was conducted using search terms related to anticoagulation, specific anticoagulant drugs, race, and ethnicity. References of identified studies were also reviewed. English-language human studies on safety or efficacy of anticoagulants reporting data for different races or ethnicities were eligible for inclusion. Results: Seventeen relevant studies were identified. The majority of major trials reviewed for inclusion either did not include representative populations or did not report on the racial breakdown of participants. Racial differences in pharmacokinetics, dosing requirements, drug response, and/or safety end points were identified for unfractionated heparin, enoxaparin, argatroban, warfarin, rivaroxaban, and edoxaban. Conclusions: Race appears to influence drug concentrations, dosing, or safety for some but not all direct oral anticoagulants. This information should be considered when selecting anticoagulant therapy for nonwhite individuals.

1 July 2019 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
CGCaitlin M. Gibson
Caitlin M. Gibson
HKHyanggi Irene Kwon
Hyanggi Irene Kwon
ATAmulya Tatachar
Amulya Tatachar